CCXI News and Press, ChemoCentryx Inc. From 02/12/22

The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, F...

-- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS ® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for t...

Shares of ChemoCentryx (NASDAQ: CCXI) , a mid-cap biopharmaceutical company , fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence . The drugmaker's shares tanked last year as a result of the protracted regulato...

Could you get a twofold return in 2022? Some stocks just might give you a good chance at achieving that goal. We asked three Motley Fool contributors which biotech stocks they think could double in the new year. Here's why they picked Adicet Bio (NASDAQ: ACET) , ChemoCentr...

Today, we shine the spotlight on InflaRx, a small biotech concern based in Germany. The stock is deep in 'Busted IPO' territory even as the company has seen an increasing amount of news flow around it in recent months. A full investment analysis follows in the paragraphs below. ...

Today, we put mid-cap biopharma name ChemoCentryx in the spotlight. The company's primary compound was recently approved for the treatment of vasculitis. A full investment analysis is presented in the paragraphs below. For further details see: Checking In On ChemoCentryx...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Single stock options trading hit a single-day high this month and $746B of single stock options expire today. "Today’s expiry could be important for stocks with large open interest in at-the-money options; market makers delta-hedging large options portfolios will be active," Goldman Sa...

The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: ChemoCentryx, Inc. 2021 Q3 - Results - Earnings Call Presentation